Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans-Reference-Cited by-同舟云学术

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Published:2013-10-30 Issue:209 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Finan Brian¹²³,Ma Tao³⁴,Ottaway Nickki⁵,Müller Timo D.¹²,Habegger Kirk M.⁵,Heppner Kristy M.⁵,Kirchner Henriette⁶,Holland Jenna⁵,Hembree Jazzminn⁵,Raver Christine⁵,Lockie Sarah H.⁷,Smiley David L.³,Gelfanov Vasily³,Yang Bin³⁸,Hofmann Susanna²,Bruemmer Dennis⁹,Drucker Daniel J.¹⁰,Pfluger Paul T.¹²⁵,Perez-Tilve Diego⁵,Gidda Jaswant⁸,Vignati Louis⁸,Zhang Lianshan⁸,Hauptman Jonathan B.¹¹,Lau Michele¹¹,Brecheisen Mathieu¹¹,Uhles Sabine¹¹,Riboulet William¹¹,Hainaut Emmanuelle¹¹,Sebokova Elena¹¹,Conde-Knape Karin¹¹,Konkar Anish¹¹,DiMarchi Richard D.³,Tschöp Matthias H.¹²⁵

Affiliation:

1. Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg 85764, Germany.

2. Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich 80333, Germany.

3. Department of Chemistry, Indiana University, Bloomington, IN 47405, USA.

4. Research Center, Beijing Hanmi Pharmaceutical, Beijing 10131, China.

5. Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA.

6. Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm 17177, Sweden.

7. Department of Physiology, Monash University, Melbourne, Victoria 3800, Australia.

8. Marcadia Biotech, Carmel, IN 46032, USA.

9. Saha Cardiovascular Research Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA.

10. Department of Medicine, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario M5G 1X5, Canada.

11. F. Hoffmann–La Roche Ltd., Basel 4070, Switzerland.

Abstract

Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. GLP-1 and energy balance: an integrated model of short-term and long-term control

2. The biology of incretin hormones

3. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

4. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes

5. Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes

Cited by 521 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics;Current Pharmaceutical Biotechnology;2024-12

2. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys;Molecular Metabolism;2024-10

3. Incretin therapy in feline diabetes mellitus – A review of the current state of research;Domestic Animal Endocrinology;2024-10

4. Tirzepatide a novel anti diabetic molecule unfold dual action;Discover Public Health;2024-09-05

5. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04